BioSenic S.A. Total Liabilities
BioSenic S.A. total liabilities. Based on the latest financial reports, BioSenic S.A. (BIOS) has total liabilities worth €28.10 Million EUR (≈ $32.85 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of BioSenic S.A. to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioSenic S.A. (2011–2024)
Total liabilities of BioSenic S.A. from 2011 to 2024. This chart illustrates how BioSenic S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore BioSenic S.A. strategic investment ratio to see how much of total assets are deployed in long-term investments.
BioSenic S.A. Competitors by Total Liabilities
The table below lists competitors of BioSenic S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BrightBid Group AB (publ)
ST:PERP-B
|
USA | Skr30.44 Million |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
USA | $359.47 Million |
|
Triangle Energy (Global) Ltd
AU:TEG
|
Australia | AU$20.25 Million |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
USA | $19.83 Million |
|
CQS Natural Resources Growth and Income plc
LSE:CYN
|
UK | GBX12.04 Million |
|
TNL Mediagene Ordinary Shares
NASDAQ:TNMG
|
USA | $49.03 Million |
|
Avrupa Minerals Ltd
V:AVU
|
Canada | CA$454.00K |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
India | Rs7.39 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down BioSenic S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BIOS asset base.
Liquidity & Leverage Metrics
BioSenic S.A. Total Liabilities Ratios Explained
BioSenic S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioSenic S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioSenic S.A. (2011–2024)
The table below shows the annual total liabilities of BioSenic S.A. from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €31.55 Million ≈ $36.89 Million |
-2.21% |
| 2023-12-31 | €32.26 Million ≈ $37.72 Million |
+23.15% |
| 2022-12-31 | €26.20 Million ≈ $30.63 Million |
-1.27% |
| 2021-12-31 | €26.54 Million ≈ $31.02 Million |
+23.37% |
| 2020-12-31 | €21.51 Million ≈ $25.15 Million |
+5.73% |
| 2019-12-31 | €20.34 Million ≈ $23.79 Million |
-4.31% |
| 2018-12-31 | €21.26 Million ≈ $24.86 Million |
-6.70% |
| 2017-12-31 | €22.79 Million ≈ $26.64 Million |
-2.25% |
| 2016-12-31 | €23.32 Million ≈ $27.26 Million |
+4.85% |
| 2015-12-31 | €22.24 Million ≈ $26.00 Million |
-33.99% |
| 2014-12-31 | €33.69 Million ≈ $39.38 Million |
+164.25% |
| 2013-12-31 | €12.75 Million ≈ $14.90 Million |
+8.22% |
| 2012-12-31 | €11.78 Million ≈ $13.77 Million |
+4.79% |
| 2011-12-31 | €11.24 Million ≈ $13.14 Million |
-- |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more